Menu Back to Complex-Drug-Device-Generic-Combination-Products

Overview

Keynote Speaker

Scott Gottlieb


Scott Gottlieb, MD, Commissioner, FDA

 

Complex Generic Drugs are a large and diverse group of products with complex active ingredients or sites of action and complex drug-device combination products. They provide important therapies to patients, for example, metered dose inhalers for treating asthma and drugs administered by auto-injectors and prefilled syringes. Because this diverse collection of drug products has one or more elements that are more complex than a simple dosage form, new complexities in the methodologies used for establishing bioequivalence are introduced, thus impeding patient access to the more affordable generic versions of these life-saving medicines.

In 2017, the FDA announced the Drug Competition Action Plan to advance new policies aimed at bringing more competition to the drug market to help reduce drug prices and improve consumer access to these much-needed medicines. The intent is to improve the efficiency of the generic drug approval process and make it easier to bring generic competition to this important category of branded drugs known as complex drugs.

Knowing that the scientific and regulatory pathways for approval of generic versions of complex products are not always well- known to generic developers, FDA intends through its policies to provide as much scientific and regulatory clarity as possible with respect to complex generic drugs. This meeting will address complex drug-device combination products, examining the science of medical device impact on drug bioequivalence in products where the drug is the primary mode of action (PMOA). The impact of devices such as auto injectors, prefilled syringes, inhalant devices, implanted delivery systems, transdermal systems, and others will be explored. The intersections of drug and device regulatory pathways and policies relating to bioequivalence studies will also be reviewed.

Join FDA staff from the CDER Office of Generic Drugs (OGD), the Office of Pharmaceutical Quality (OPQ), CDRH, the Office of Combination Products (OCP), and industry experts to discuss the knowns, unknowns, and the role of modeling in the development of these important products.


NEW! Travel Once, Save Twice!
This year, DIA's Complex Drug-Device Generic Combination Products Meeting will be co-located with DIA's Combination Products Conference. Maximize your education and time by attending both! Save* $100 when you register for both events!
*You must register for both events at the same time for the discount to be applied.

Exclusive Podcast

Take a listen to our podcast with Maryll Toufanian, Acting Director, US FDA Office of Generic Drug Policy. “In order for FDA to approve a generic drug, a generic manufacturer must submit scientific information supporting the generic drug’s ‘sameness’ to the brand.”

Listen In


Additional Resources - On-Demand Generics Webinar Series

Learning objectives

At the conclusion of this Meeting, participants should be able to:

  • Understand the current regulatory landscape for generic combination drug-device products, including recent general and product-specific guidance documents
  • Examine the scientific concerns and recent research advances associated with the development of generic drug-device combination products
  • Recognize important drug and device manufacturing review issues when it comes to quality assurance for these combination products.
  • Apply these regulatory approaches and scientific concerns to specific example combination products such as orally inhaled and nasal drug products, auto-injected drug products, and transdermal delivery systems

Program Committee

  • Markham  Luke, MD, PhD
    Markham Luke, MD, PhD Director, Division of Therapeutic Performance, Office of Generic Drugs,CDER
    FDA, United States
  • Andrew A. LeBoeuf, JD, MS
    Andrew A. LeBoeuf, JD, MS Regulatory Counsel, Office of Generic Drug Policy, CDER
    FDA, United States
  • Patricia Y. Love, MD, MBA
    Patricia Y. Love, MD, MBA Deputy Director, Office of Combination Products, OSPM, OMPT
    FDA, United States
  • Brian  McCormick
    Brian McCormick Vice President - Chief Regulatory Counsel
    Teva Pharmaceuticals, United States
  • John  Peters, MD
    John Peters, MD Deputy Director, Office of Generic Drugs, CDER
    FDA, United States
  • Susan M. Rosencrance, PhD
    Susan M. Rosencrance, PhD Director, Office of Lifecycle Drug Products, OPQ, CDER
    FDA, United States
  • Alan  Stevens
    Alan Stevens ME in Reliability Engineering
    FDA, United States
  • Roisin   Wallace
    Roisin Wallace
    Mylan Global Device Development, Ireland
  • Kimberly  Witzmann, MD
    Kimberly Witzmann, MD Division of Therapeutic Performance, Office of Generic Drugs, CDER
    FDA, United States
  • Jason  Woo, MD, MPH
    Jason Woo, MD, MPH Senior Medical Officer, Office of Generic Drugs, CDER
    FDA, United States
  • Geoffrey  Wu, PhD
    Geoffrey Wu, PhD Associate Director, OLDP, OPQ, CDER
    FDA, United States
  • Lei  Zhang, PhD
    Lei Zhang, PhD Deputy Director, Office of Research & Standards, Office of Generic Drugs, CDER
    FDA, United States
Load More

Contact us

Registration Questions?

Send Email
1.888.257.6457


Co-located Meeting

Combination Products Conference
*Save $100 when you register for both at the same time!


Digital Learning Catalog

DIA Learning: 2018 eLearning Soultions
Download